# A Study of QLF32101 in Patients With Acute Myeloid Leukemia and Myelodysplastic Syndrome

> **NCT05703204** · PHASE1 · UNKNOWN · sponsor: **Qilu Pharmaceutical Co., Ltd.** · enrollment: 122 (estimated)

## Conditions studied

- Acute Myeloid Leukemia and Myelodysplastic Syndrome

## Interventions

- **DRUG:** QLF32101

## Key facts

- **NCT ID:** NCT05703204
- **Lead sponsor:** Qilu Pharmaceutical Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2023-02-01
- **Primary completion:** 2024-08-21
- **Final completion:** 2024-12-21
- **Target enrollment:** 122 (ESTIMATED)
- **Last updated:** 2023-01-31


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05703204

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05703204, "A Study of QLF32101 in Patients With Acute Myeloid Leukemia and Myelodysplastic Syndrome". Retrieved via AI Analytics 2026-06-08 from https://api.ai-analytics.org/clinical/NCT05703204. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*